Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Retained Earnings (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Retained Earnings readings, the most recent being -$309.6 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 20.33% to -$309.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$309.6 million, a 20.33% decrease, with the full-year FY2025 number at -$304.1 million, down 27.95% from a year prior.
  • Retained Earnings hit -$309.6 million in Q1 2026 for Barinthus Biotherapeutics, down from -$304.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$82.1 million in Q3 2022 to a low of -$309.6 million in Q1 2026.
  • Median Retained Earnings over the past 5 years was -$192.1 million (2024), compared with a mean of -$193.1 million.
  • Biggest five-year swings in Retained Earnings: increased 12.22% in 2022 and later plummeted 94.14% in 2023.
  • Barinthus Biotherapeutics' Retained Earnings stood at -$103.2 million in 2022, then tumbled by 71.04% to -$176.6 million in 2023, then plummeted by 34.59% to -$237.7 million in 2024, then decreased by 27.95% to -$304.1 million in 2025, then dropped by 1.82% to -$309.6 million in 2026.
  • The last three reported values for Retained Earnings were -$309.6 million (Q1 2026), -$304.1 million (Q4 2025), and -$293.0 million (Q3 2025) per Business Quant data.